201 related articles for article (PubMed ID: 12187268)
1. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
[TBL] [Abstract][Full Text] [Related]
5. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Saeid MS; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1999 May; 53(5):939-44. PubMed ID: 10223487
[TBL] [Abstract][Full Text] [Related]
6. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
7. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
Adlakha H; Bostwick DG
Hum Pathol; 1994 Feb; 25(2):135-9. PubMed ID: 7509774
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sweat SD; Pacelli A; Murphy GP; Bostwick DG
Urology; 1998 Oct; 52(4):637-40. PubMed ID: 9763084
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
11. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
[TBL] [Abstract][Full Text] [Related]
12. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
14. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma.
Bostwick DG; Dousa MK; Crawford BG; Wollan PC
Am J Surg Pathol; 1994 Dec; 18(12):1240-6. PubMed ID: 7977947
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
18. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
[TBL] [Abstract][Full Text] [Related]
20. Cancer volume of lymph node metastasis predicts progression in prostate cancer.
Cheng L; Bergstralh EJ; Cheville JC; Slezak J; Corica FA; Zincke H; Blute ML; Bostwick DG
Am J Surg Pathol; 1998 Dec; 22(12):1491-500. PubMed ID: 9850175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]